Changes to the Bachem CEC and strengthening of the US organization

Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX

Changes to the Bachem Corporate Executive Committee and strengthening of the organization in North America

  • Torsten Wöhr to join the CEC as Chief Marketing Officer (CMO)
  • Anne-Kathrin Stoller to take on a new role as Chief Operating Officer Bachem Americas, reporting directly to the CEO

Bachem (SIX: BANB) announced today that, effective March 1, 2022 Anne-Kathrin Stoller will take on a new role as Chief Operating Officer for Bachem Americas. This role will be elevated by reporting directly to the CEO of Bachem, Thomas Meier, and receive expanded responsibilities for the organization in North America. She will be succeeded as Chief Marketing Officer on the Corporate Executive Committee by Torsten Wöhr, who will also report to the CEO.

With this development, Bachem aims to further strengthen its presence and visibility in the North America region where it operates two GMP-sites in Torrance, CA and Vista, CA.

Anne-Kathrin Stoller has been with Bachem since 2006 and has held roles of increasing responsibility at the company, including Head of Business Development & Sales for Europe and had served as CMO since January 1, 2018. She studied chemistry in Hannover (Germany) and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel (Switzerland).

Torsten Wöhr joined Bachem in 2017 as Sales Director for the generic API business and has led Bachem’s oligonucleotide program since 2019. Previously he held commercial leadership roles in various pharmaceutical manufacturing and life sciences companies in the United States and Europe. He studied biochemistry & molecular biology at the Swiss Federal Institute of Technology (ETH) Zurich and holds a doctorate in bioorganic chemistry from the University of Lausanne/EPFL and a postgraduate degree in Industrial Engineering and Management, ETH Zurich.

Anne-Kathrin Stoller will bring strong customer-facing expertise to a key market in a newly elevated COO Bachem Americas role. Torsten Wöhr has been instrumental in driving Bachem’s entry into the oligonucleotides business. I am grateful that Bachem can continue to fill critical positions with internal talent who have both strong leadership track records, as well as recognized expertise in the fields of peptides and oligonucleotides. I thank both Anne-Kathrin Stoller and Torsten Wöhr for the service to date to Bachem and look forward to working closely with both in their new roles.

Thomas Meier

CEO, Bachem

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Press release in English

Press release in German

For more information:

Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications

Media: media[at]
Investors: ir[at]